
Objectives: During sepsis, circulating cell-free mitochondrial DNA (ccf-mtDNA) is released and elevated due to cell injury, augments the immune response, and may contribute to organ dysfunction. Delirium is common and deleterious during sepsis, but little is known about the relationship between mitochondrial injury and delirium during sepsis. We sought therefore to examine associations between ccf-mtDNA and delirium and other clinical outcomes during sepsis. Design: Multicenter, prospective cohort study. Setting: Medical and surgical ICUs in university and community hospitals in Nashville, TN. Patients: Four hundred eighty patients with sepsis plus shock and/or acute respiratory failure. Interventions: None. Measurements and Main Results: We measured ccf-mtDNA in plasma collected on multiple days (study days 1, 3, and 5) during sepsis and assessed participants bid for delirium and coma using the validated Confusion Assessment Method for the ICU and Richmond Agitation-Sedation Scale. We then assessed survivors’ cognitive function 3 and 12 months after hospital discharge using the Repeatable Battery for the Assessment of Neuropsychological Status. During sepsis, the adjusted odds of delirium were 7% lower for individuals at the 75th percentile of ccf-mtDNA compared with those at the 25th percentile (odds ratio [OR], 0.93; 95% CI, 0.86–0.99; p = 0.048). ccf-mtDNA was marginally associated with in-hospital mortality (hazard ratio, 1.09; 95% CI, 0.99–1.20; p = 0.08), but was not associated with coma (OR, 0.98; 95% CI, 0.90–1.05; p = 0.31) or 3-month (beta, 0.23; 95% CI, –1.58 to 2.05; p = 0.80) and 12-month (beta, –0.36; 95% CI, –2.13 to 1.42; p = 0.69) cognitive outcomes. Conclusions: In this multicenter, prospective cohort study, higher levels of ccf-mtDNA were associated with lower odds of delirium, a result that contradicted our hypothesis. This provocative finding should be interpreted cautiously until replicated and explained by future studies.
Objectives: Urgent ICU consultation is intended to elicit advice and consider ICU transfer. Our objective was to describe the nature and outcomes of ICU consultations across a global cohort. Design: This is a secondary analysis of patients with one or more ICU consultations. A care episode was defined as consecutive urgent ICU consultations until an ICU admission or at least 2 weeks without an urgent ICU consultation. We describe consultation outcomes for the last care episode. Late escalations were defined by a Children’s Resuscitation Intensity Scale score greater than 2. Setting: Twenty-one centers participating in the Evaluation of Processes of Care and the Outcomes of Children in Hospital (EPOCH) cluster-randomized trial. Patients: There were 4288 urgent ICU consultations in 3625 care episodes for 3000 patients with a median (interquartile range) age of 25 months (5–99 mo). Interventions: In the parent EPOCH trial, hospitals were randomized to Bedside Pediatric Early Warning System or usual care; no intervention was assigned in this secondary analysis. Measurements and Main Results: The outcomes of the 3000 last care episodes were in-consultation death in three (0.1%) and urgent ICU admission in 1477 (49.2%). Among 3000 first, 400 second, and 68 third consultations, the proportions of ICU admission were 42%, 44%, and 47%. The proportions of ICU admissions that were late escalation were similar across groups: 18% for first and second urgent ICU consultations, and 25% for third urgent ICU consultations. among patients having a second urgent ICU consultation, patients who had received resuscitation interventions in their first urgent ICU consultation (and remained on the ward) had more frequent resuscitation events (23.2% vs. 3.4%, p < 0.01) and had a similar frequency of late escalation (31.8% vs. 15.6%, p = 0.07) and ICU admission (51.1% vs. 43.1%, p = 0.40) compared with patients without resuscitation in their first urgent ICU consultation. Conclusions: Urgent consultation to the ICU is common during pediatric hospitalization. Repeated ICU consultation was associated with a similar frequency of late escalation. Resuscitation measures were provided in one of 12 ICU consultations where patients were not admitted to ICU and were a risk factor for late escalation in subsequent consultations.
Objectives: This trial emulation aimed to answer the question: Among patients with acute respiratory distress syndrome (ARDS) who receive lung protective ventilation with low tidal volume, is normocapnia through an increase in respiratory rate associated with lower mortality than mild hypercapnia? Design: Target trial emulation. Setting: Hospitals of the ARDS Network and Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. Patients: Patients with ARDS enrolled in seven ARDS Network and PETAL Network randomized controlled trials. Interventions: None. Measurements and Main Results: A target trial was emulated, assigning participants in a 1:1 ratio to normocapnia (target Pa co 2 35–45 mm Hg) or mild hypercapnia (target Pa co 2 50–55 mm Hg) for 4 days following the initiation of lung protective ventilation. The primary outcome was 90-day in-hospital mortality. Of 5367 potentially eligible subjects, 292 patients were assigned to normocapnia and 292 to mild hypercapnia. Separation in Pa co 2 values was preserved over the 4-day period of emulated intervention. Both groups had median pH greater than or equal to 7.33. Bicarbonate levels, driving pressure, tidal volume, and dead-space fraction did not differ clinically significantly between groups, while median respiratory rate was 33.0 breaths/min in the normocapnia vs. 28.0 breaths/min in the mild hypercapnia group ( p < 0.001). Death within 90 days occurred in 84 of 292 patients (28.8%) in the normocapnia group and in 84 of 292 patients (28.8%) in the mild hypercapnia group (log-rank p = 0.842). This result persisted in subgroups such as older (≥ 65 yr) and obese (body mass index ≥ 30 kg/m 2 ) patients. Conclusions: Among patients with ARDS who received lung protective ventilation, normocapnia through an increase in respiratory rate was not associated with lower mortality than mild hypercapnia. As this finding is derived from a trial emulation, it should be interpreted cautiously given the potential for significant residual bias.
Objectives: To evaluate the discrimination and calibration of the Sequential Organ Failure Assessment (SOFA)-2 score for ICU mortality across demographic subgroups defined by age, sex, race and ethnicity, primary language, and insurance status. Design: Retrospective cohort study. Setting: Single academic medical center in the northeastern United States (Beth Israel Deaconess Medical Center, Boston, MA), using the Medical Information Mart for Intensive Care-IV database (version 3.1), 2008–2022, a dataset external to the SOFA-2 development cohort. Patients: Adult patients (≥ 18 yr) with at least one ICU admission. The first ICU admission of the first qualifying hospitalization per patient was analyzed. Interventions: None. Measurements and Main Results: First-day SOFA-2 scores were calculated from the worst values recorded during the first 24 hours of ICU admission across six organ systems, with ICU mortality as the primary outcome. Discrimination was assessed using the area under the receiver operating characteristic curve (AUROC) and calibration using intercept and slope, with subgroup differences in AUROC estimated by bootstrap resampling. Among 64,015 ICU patients (mean [ sd ] age, 64.6 [17.1] yr; 56.1% male; 66.1% White), overall AUROC was 0.77 (95% CI, 0.76–0.77). Discrimination declined significantly with age: AUROC, 0.85 (0.83–0.87) for ages 18–44 years vs. 0.72 (0.70–0.73) for ages 75 or older (ΔAUROC, −0.14 [95% CI, −0.16 to −0.11]), with systematic underprediction in older patients. Discrimination was significantly decreased among non-English speakers (ΔAUROC, −0.04) but did not differ across documented racial/ethnic groups. Patients with missing demographic information had markedly higher mortality than the overall cohort rate of 7.2% (14.1% for missing race/ethnicity; 23.1% for missing language). Conclusions: SOFA-2 demonstrated good overall performance but with clinically meaningful variation across subgroups, particularly with age and language. Patients with missing demographic data experienced markedly higher mortality. These findings argue for routine equity evaluation as a complement to traditional validation of clinical prediction tools.
Delirium is an abnormal mental status, commonly occurring among critically ill patients, in which a person’s attention and awareness change acutely. Delirium is associated with negative outcomes, including death. Furthermore, a longer duration of delirium is associated with long-term cognitive impairment in survivors of critical illness. Hence, there is a need for novel interventions that reduce the duration of delirium; however, measuring and analyzing “duration of delirium” as an endpoint in randomized trials is challenging due to the episodic nature of delirium and the competing events of coma and death, which can bias analyses of duration of delirium. Given these challenges, delirium trials have adopted one of two composite endpoints: delirium- and coma-free days, defined as the number of days alive without delirium or coma for both survivors and nonsurvivors, and an alternative composite that ranks death as the worst state and orders days alive without delirium or coma among survivors. To date, these composite endpoints have not been rigorously evaluated. Hence, herein we use data from the Maximizing Efficacy of Targeted Sedation and Reducing Neurologic Dysfunction (MENDS) trial to motivate the use of composite endpoints in critical care delirium trials, discuss how to define the effect of treatment on each composite endpoint and their clinical interpretability, and present a method for visualizing how the treatment effects accrue over the course of follow-up. Based on these analyses, we provide practical recommendations for the use of composite endpoints in critical care delirium trials, which could be extended to other randomized trials that rely on similar composite endpoints.